Uncovering The Role Of Collecting Lymphatic Vessels In Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$688,875.00
Summary
Lymphatic vessels are a critical part of the circulatory system, allowing the return of fluid and cells that escape the blood vessels, and playing an intimate role in the body's immune function. In cancer, the lymphatic vessels serve as conduits for the transport of tumour cells to lymph nodes and may contribute to distant metastasis. Our study is designed to understand the role played by major collecting lymphatic vessels in cancer and to identify molecules that control their activity.
An Investigation Into The Role Of 3’UTR Dynamics In Breast Cancer Metastasis
Funder
National Health and Medical Research Council
Funding Amount
$627,444.00
Summary
Basic research has brought many improvements to the diagnosis and treatment of cancer. An exception are the triple negative breast cancers. No targeted therapies yet exist, and thus a combination of chemotherapy, surgery and radiation therapy is the only option. For 2/3rds of women this works well and survivor rates are high, but the prognosis is poor for those that do not respond. This research aims to reveal therapeutic opportunities to block the potential of such tumours to spread.
Transient Tissue ‘priming’ Via FAK Inhibition To Impair Pancreatic Cancer Progression And Improve Sensitivity To Gemcitabine/Abraxane
Funder
National Health and Medical Research Council
Funding Amount
$643,848.00
Summary
The success of cancer drugs is dependent on many factors including the properties of the tumour tissue. As a tumour grows it changes the tissue around it, and this affects response to treatment. Combining classical biology with engineering to generate 3D models that mimic tumours, along with cutting-edge imaging technology and mouse models, we will target FAK-controlled cancer cell pathways that sense tissue changes, together with already approved cancer drugs to improve patient outcome.
Single-cell Optical Window Imaging In CDK1-FRET Biosensor Mice To Assess Tissue Stiffness And Optimise Delivery And Therapeutic Response To Gemcitabine/Abraxane In Pancreatic Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$676,979.00
Summary
Inefficient drug response in solid tumour tissue is commonly a limiting factor in the clinical effectiveness of cancer therapies. Using cutting-edge imaging technology and 3D models that mimic the disease, we have mapped areas of poor drug response within distinct regions of tumours. Here, we pinpoint and specifically target key factors limiting efficient drug targeting in order to improve the encouraging anti-cancer profile of the new drug combination Gemcitabine/Abraxane in pancreatic cancer.
Real-time Optical Window Imaging Of AKT-FRET Biosensor Mice To Maximise PI3K/AKT Drug Targeting Within The Hypoxic Microenvironment Of Pancreatic Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$683,447.00
Summary
Inefficient drug response in solid tumour tissue is often a limiting factor in the clinical effectiveness of cancer therapies. Using cutting-edge imaging technology and 3D models that mimic the disease, we have mapped areas of poor drug response within distinct regions of tumours with low oxygen levels known as hypoxia. Here, we will specifically target factors limiting efficient drug targeting in these areas to improve the encouraging anti-cancer profile of AKT inhibitors in pancreatic cancer.
Genetic Engineering Of Tumor-infiltrating Monocytes To Inhibit Primary And Metastatic Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$792,470.00
Summary
The immunosuppressive environment within a tumour is the major impediment to the successful application of cancer immunotherapy. To address this, we developed a cell- and gene-based strategy for targeted delivery of a potent immune-stimulatory molecule, IFN-?, which activates the immune response at the site of the tumour. We now propose to combine this strategy with promising cancer immunotherapies for the treatment of advanced breast cancer and breast cancer metastasis.
PARP And PI3K Inhibition In Pancreatic Cancer: Intravital Insights And ‘fine-tune’ Priming Using AKT And Single/double-strand DNA Break Biosensor Mice.
Funder
National Health and Medical Research Council
Funding Amount
$760,505.00
Summary
Inefficient drug response in solid tumour tissue is often a limiting factor in the clinical effectiveness of cancer therapies. Using cutting-edge imaging technology and 3D models that mimic the disease, we can map areas of poor drug response within distinct regions of tumours with chemotherapy. Here, we will shift factors limiting efficient drug targeting in these areas to improve the encouraging anti-cancer profile of PI3K and DNA repair inhibitors in pancreatic cancer.
Investigating Signalling Pathways That Mediate Suppression Of Anoikis By Chemokine Receptors In Metastatic Breast Cancer Cells
Funder
National Health and Medical Research Council
Funding Amount
$597,349.00
Summary
This research aims at understanding the "nuts and bolts" of the main killer in cancer patients - tumour metastasis. We will look for molecules that are specific to metastatic tumour cells that transmit signals from the cell surface to the cell "suicide" machinery and prevent metastatic cancer cell death.
Understanding Cancer Development And Metastasis Through Regulation Of Cell Plasticity
Funder
National Health and Medical Research Council
Funding Amount
$773,103.00
Summary
I aim to understand how cancer cells switch between non-aggressive and aggressive cell states, and to determine how these processes contribute to cancer development and progression. In determining the factors that drive these processes I aim to discover novel strategies for deriving effective therapies for patients with aggressive and advanced-stage cancer.